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Background
Radiotherapy (RT) can induce T cell-mediated anti-
tumor immune responses by multiple mechanisms.
However, due to the strongly immunosuppressive tumor
microenvironment that hinders T cell function, these
responses are ineffective and tumors usually escape. The
common gamma-chain cytokines interleukin ( IL)-2 and
IL-15 promote the proliferation of activated T cells and,
therefore, are prime agents for immunotherapy strate-
gies aimed at sustaining anti-tumor T cell responses. IL-
2 at high doses is effective at inducing responses in a
subset of cancer patients. However, the benefits of IL-2
are partially offset by serious toxicity and by regulatory
T cell (Treg) stimulation. IL-15, on the other hand, has
shown low toxicity and lacks Treg stimulatory activity,
making it an attractive candidate for testing in combina-
tion with RT. Here we tested the hypothesis that IL-15
administration strengthens the pro-immunogenic effect
of hypofractionated RT and contributes to inducing
effective anti-tumor responses.
Methods
The poorly immunogenic TSA mouse breast cancer cells
were implanted s.c. in syngeneic BALB/c mice on day 0.
When tumors became palpable, mice were randomly
assigned to one of 4 treatment groups (N = 4-5mice/
group): control, RT, IL-15 or RT+IL-15. RT was deliv-
ered exclusively to the primary tumor in 8 Gy fractions
on days 13, 14 and 15. IL-15 (5 μg/mouse) was adminis-
tered i.p. or s.c. peritumorally daily for 10 days starting
on day 12. Mice were followed for tumor growth or
regression. In a separate experiment, mice were eutha-
nized on day 22 to characterize tumor-infiltrating lym-
phocytes (TILs).
Results
Tumor growth delay was seen when IL-15 was given
peritumorally but not i.p. (p < 0.05 compared to con-
trol). Improved tumor regression was seen when RT
was combined with IL-15 (p < 0.05), suggesting that IL-
15 can potentiate T cell responses elicited by RT. Con-
sistently, analysis of TILs showed a marked increase in
CD8+ T cells expressing the activation marker CD137
(35.3% in RT+IL-15 versus 5.90% In control, p < 0.05)
while the increase was modest with each monotherapy
(18.8% in RT, 20.7% in IL-15, p < 0.05 compared to
control). In addition, we found a significant increase in
the ratio of effector CD4+ T-cells to Tregs (2.5 in RT
+IL-15 versus 0.78 in control, p < 0.05) whereas mono-
therapy had no effect (1.14 in RT, 0.96 in IL-15).
Conclusions
Overall these results support the hypothesis that IL-15 is
a valuable partner for combination treatments with local
RT. We are currently elucidating the mechanisms
involved in pre-clinical models in preparation for future
testing in patients.
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